TLDR Diphencyprone helped most patients with alopecia areata regrow some hair.
This retrospective review of diphencyprone (DCP) treatment for alopecia areata (AA) over 20 years included 205 treatment courses for 133 patients. Results showed that 72.2% of patients experienced some hair regrowth, with 15.8% achieving over 90% regrowth, while 27.1% had no response. Significant predictors of treatment outcome were the extent of alopecia at baseline and disease duration, whereas atopy, age at onset, and nail dystrophy were not significant. The study highlighted the need for better data collection, particularly for long-term outcomes, and suggested exploring DCP self-administration and assessing maintenance therapy objectively. Limitations included its retrospective nature and lack of long-term follow-up data.
701 citations,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
218 citations,
April 2012 in “British Journal of Dermatology” Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.
421 citations,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
37 citations,
September 2009 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Diphencyprone (DPC) is an effective and safe long-term treatment for alopecia areata, especially with maintenance therapy.
164 citations,
April 2008 in “Cochrane library” Current treatments for alopecia show no significant long-term benefits.
132 citations,
November 1998 in “Journal of the American Academy of Dermatology” Topical sensitizers have mixed success in treating alopecia areata.
April 2019 in “International journal of research in dermatology” A child with rough nails also had hair loss and allergies.